Form 8-K - Current report:
SEC Accession No. 0001213900-25-060352
Filing Date
2025-07-01
Accepted
2025-07-01 16:01:31
Documents
14
Period of Report
2025-07-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0247670-8k_oruka.htm   iXBRL 8-K 33240
2 OFFER LETTER, DATED JULY 1, 2025, BETWEEN ORUKA THERAPEUTICS, INC. AND LAURA SAN ea024767001ex10-1_oruka.htm EX-10.1 67914
3 GRAPHIC ex10-1_001.jpg GRAPHIC 21004
  Complete submission text file 0001213900-25-060352.txt   315377

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE orka-20250701.xsd EX-101.SCH 3011
5 XBRL LABEL FILE orka-20250701_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE orka-20250701_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0247670-8k_oruka_htm.xml XML 3678
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 251096201
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)